Helen Boucher is the Chief of the Division of Geographic Medicine and Infectious Diseases and Director of the Tufts Center for Integrated Management of Antimicrobial Resistance (CIMAR), a collaborative, cross-disciplinary initiative between Tufts University and Tufts Medical Center with a mission of innovating to protect humanity from the global threat of antimicrobial resistance by integrating solutions across human and veterinary medicine, stewardship and awareness. She is Director of TMC’s Heart Transplant and Ventricular Assist Device Infectious Diseases Program, and Professor of Medicine at Tufts University School of Medicine. Dr. Boucher’s clinical interests include infections in immunocompromised patients and S. aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the author or coauthor of numerous abstracts, chapters, and peer-reviewed articles, which have been published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and The Annals of Internal Medicine; she is Associate Editor of Antimicrobial Agents and Chemotherapy. In 2015, Dr. Boucher was appointed a voting member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, and elected Treasurer of the Infectious Diseases Society of America. She was awarded the IDSA Society Citation Award in October, 2015. Dr. Boucher serves on the Board of Trustees of The College of the Holy Cross and as Chair of the Board of Trustees of the Physicians of Tufts Medical Center.

Natasha Hochberg, MD, MPH is Associate Professor in the Department of Medicine (Section of Infectious Diseases) at Boston University School of Medicine and in the Department of Epidemiology at BU School of Public Health. She is also the Program Director for the Infectious Disease Fellowship Program. Prior to her arrival at BU, Dr. Hochberg was an Epidemic Intelligence Service (EIS) officer at the Centers for Disease and Prevention (CDC) in the Division of Parasitic Diseases and worked internationally on projects related to malaria and other diseases. She is the co-director of the travel clinic at Boston Medical Center (BMC) where she sees travelers and patients with tropical diseases, and she attends on the inpatient infectious disease consult service. She serves as the co-site director for GeoSentinel, an international surveillance system of diseases in travelers and migrants. At a national level, she is part of the American Society of Tropical Medicine and Hygiene where she serves as a Councilor for the Clinical Group, as a member of the Scientific Program Committee, and as the Chair for the Subcommittee on Pneumonia, Respiratory Infections and TB. Dr. Hochberg’s research focuses on tropical diseases. Particularly, she studies the impact of malnutrition and parasitic disease on tuberculosis (TB), tropical diseases in immigrant populations, and preventing diseases in international travelers. Dr. Hochberg has taught courses at BU School of Public Health on Infectious Disease Epidemiology and Outbreak Investigations.

Christopher Locher, PhD is a co-founder and CEO of Versatope Therapeutics, a Lowell-based company focused on the development of a universal influenza vaccine. He has led drug discovery and development projects by coordinating the internal activities of R&D teams with external development support, key opinion leaders and biotechnology alliances. He was previously a Senior Director at Vertex Pharmaceuticals where he was responsible for establishing infectious disease external R&D programs. Prior to that, he was the VP of Preclinical Development at Opsona Therapeutics in Dublin, Ireland and helped build the team and pipeline with new products (biologics and new chemical entities). At Maxygen in California, he the project leader for government funded vaccine development programs for malaria and alphaviruses. He completed postdoctoral training at the University of California, San Francisco, was a Fulbright Hayes Research Fellow at the Institute of Tropical Medicine in Antwerp, Belgium and received his PhD in Tropical Medicine and BA in Biological Sciences from the University of Hawaii.

Manos Perros, Ph.D., has served as chief executive officer, co-founder and director at Entasis Therapeutics since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc.